A deep reinforcement learning framework optimizes silicon-based photonic crystal fiber modulators, achieving ultra-low ...

Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Fine-scale exogenous attention within the foveola selectively enhances contrast gain at low-to-mid spatial frequencies while increasing response gain across a broad spatial frequency range.

(NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line ...

Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data from ...

Top line data readout expected in late Q3/early Q4; INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Modern OCT devices can look inside the eye without a scalpel - but they do not always capture everything that matters. Some ...